Woo K T
Department of Renal Medicine, Singapore General Hospital, Singapore.
Singapore Med J. 1999 Apr;40(4):310-3.
All clinical trials in Singapore will now have to conform to the Medicines (Clinical Trials) Amended Regulations 1998 and the Singapore Good Clinical Practice (GCP) Guidelines 1998. The Medical Clinical Research Committee (MCRC) has been established to oversee the conduct of clinical drug trials in Singapore and together with the legislations in place, these will ensure that clinical trials conducted in Singapore are properly controlled and the well-being of trial subjects are safe guarded. All clinical drug trials require a Clinical Trial Certificate from the MCRC before the trial can proceed. The hospital ethics committee (EC) vets the application for a trial certificate before it is sent to MCRC. The drug company sponsoring the trial has to indemnify the trial investigators and the hospital for negligence arising from the trial. The MCRC, apart from ensuring the safety of trial subjects, has to provide continuing review of the clinical trial and monitors adverse events in the course of the trial. The EC will conduct continuing review of clinical trials. When a non-drug clinical trial is carried out, the EC will ensure that the proposed protocol addresses ethical concerns and meets regulatory requirements for such trials. There is great potential for pharmaceutical Research & Development (R&D) in Singapore. We must develop our skills and infrastructure in clinical trials to enable Singapore to be a regional hub for R&D of drugs in Asia.
新加坡所有的临床试验现在都必须符合1998年《药品(临床试验)修订条例》以及1998年《新加坡良好临床实践(GCP)指南》。医学临床研究委员会(MCRC)已成立,以监督新加坡临床药物试验的开展,并且连同现有的法规一起,这些将确保在新加坡进行的临床试验得到适当控制,试验受试者的福祉得到保障。所有临床药物试验在试验能够进行之前都需要获得医学临床研究委员会颁发的临床试验证书。医院伦理委员会(EC)在将试验证书申请送交医学临床研究委员会之前会对其进行审核。开展试验的制药公司必须就试验引发的疏忽对试验研究者和医院作出赔偿。医学临床研究委员会除了确保试验受试者的安全之外,还必须对临床试验进行持续审查,并监测试验过程中的不良事件。伦理委员会将对临床试验进行持续审查。当开展非药物临床试验时,伦理委员会将确保拟定的方案解决伦理问题并符合此类试验的监管要求。新加坡在制药研发方面有巨大潜力。我们必须发展我们在临床试验方面的技能和基础设施,以使新加坡成为亚洲药物研发的区域中心。